These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. [Present state of heparin therapy]. Blatrix C, Soulier JP, Vacheron A, Cornu P. Presse Med (1893); 1969 Mar 26; 77(15):553-6. PubMed ID: 5796027 [No Abstract] [Full Text] [Related]
3. Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients. Low CL, Bailie G, Morgan S, Eisele G. Clin Nephrol; 1996 Feb 26; 45(2):120-4. PubMed ID: 8846524 [Abstract] [Full Text] [Related]
4. The effectiveness of implementing the weight-based heparin nomogram as a practice guideline. Raschke RA, Gollihare B, Peirce JC. Arch Intern Med; 1996 Feb 26; 156(15):1645-9. PubMed ID: 8694662 [Abstract] [Full Text] [Related]
6. [Control of the heparin induced bleeding risk in haemodialysis patients (author's transl)]. Vogel GE, Kopp KF. Med Klin; 1976 Jan 16; 71(3):116-9. PubMed ID: 1250190 [Abstract] [Full Text] [Related]
7. Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. Anand SS, Yusuf S, Pogue J, Ginsberg JS, Hirsh J, Organization to Assess Strategies for Ischemic Syndromes Investigators. Circulation; 2003 Jun 17; 107(23):2884-8. PubMed ID: 12796128 [Abstract] [Full Text] [Related]
9. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Hull RD, Raskob GE, Brant RF, Pineo GF, Valentine KA. Arch Intern Med; 2003 Jun 17; 157(22):2562-8. PubMed ID: 9531224 [Abstract] [Full Text] [Related]
10. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?]. Sefer S, Kes P, Raić B, Heinrich B, Degoricija V, Szavits-Nossan J. Acta Med Croatica; 2006 Jun 17; 60(3):281-5. PubMed ID: 16933844 [Abstract] [Full Text] [Related]
13. Rationale for the use of a low molecular weight heparin during hemodialysis with polysulphone membrane in uremic patients. Moia M, Graziani G, Tenconi PM, Martinelli I, Ponticelli C. Ann Ital Med Int; 1997 Jun 17; 12(2):67-71. PubMed ID: 9284597 [Abstract] [Full Text] [Related]